Related Experiment Video

Updated: Jun 19, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention

Rabih R Azar1, Georges Badaoui, Antoine Sarkis

  • 1Division of Cardiology, Hotel Dieu de France Hospital Beirut, Lebanon. razar@usj.edu.lb

Clinical Cardiology
|October 10, 2009
PubMed

Insights

High-dose tirofiban did not reduce inflammatory markers in most patients undergoing percutaneous coronary intervention (PCI). However, it did reduce C-reactive protein in diabetic patients, suggesting potential anti-inflammatory effects in higher-risk populations.

Area of Science:

  • Cardiology
  • Pharmacology
  • Inflammation Research

Background:

  • Tirofiban at standard doses has limited anti-inflammatory effects post-PCI.
  • Higher doses may improve platelet inhibition but anti-inflammatory benefits are unknown.

Purpose of the Study:

  • To investigate the anti-inflammatory activity of high-bolus dose tirofiban during PCI.

Main Methods:

  • 100 patients undergoing PCI were randomized to high-dose tirofiban or saline.
  • Exclusion criteria included elevated troponin or thrombus.
  • Inflammatory markers (IL-6, hs-CRP) were measured at baseline and 24 hours.

Main Results:

  • Tirofiban ( >90% platelet aggregation inhibition) did not reduce IL-6 or hs-CRP increases.
  • In diabetic patients, tirofiban significantly reduced hs-CRP rise by 65% (p=0.01) but not IL-6.
  • No significant difference in inflammatory marker changes between tirofiban and control groups overall.

Conclusions:

  • High-bolus dose tirofiban did not attenuate inflammatory marker rise in low-risk PCI patients.
  • Tirofiban demonstrated potential anti-inflammatory activity in diabetic patients, suggesting benefit in higher-risk groups.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...